Sonoma Pharmaceuticals (NASDAQ:SNOA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. “
SNOA has been the topic of a number of other research reports. Maxim Group set a $11.00 target price on Sonoma Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 17th. Benchmark assumed coverage on Sonoma Pharmaceuticals in a report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 target price on the stock.
TRADEMARK VIOLATION WARNING: This article was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/01/11/sonoma-pharmaceuticals-snoa-downgraded-by-zacks-investment-research-to-hold.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.